Bio Break: Why Don’t We Have a Cortisol-Sensing Wearable Yet?
In this Bio Break episode, Nick Allan and Joris van der Heijden tackle a question many tech and health enthusiasts have wondered for years: Where is my cortisol-sensing wearable? Nick shares a nostalgic story of reading about futuristic wearable technology in Popular Mechanics as a child — devices that would one day monitor biomarkers like cortisol to track stress and overall health. Now, decades later, he and Joris break down why such a wearable device still hasn’t become a reality.
Joris explains that although cortisol biosensors and other advanced wearable diagnostics often show up in academic research, turning those scientific breakthroughs into viable consumer products is a much bigger challenge. First, there’s the technical difficulty of converting a sensitive laboratory assay for cortisol into a fully automated, real-time wearable device that could be used reliably outside of controlled lab settings. Measuring something like cortisol, potentially via interstitial fluid or sweat, involves complex fluidic and sensing systems that must function accurately and consistently on a wearable platform.
Second — and often the biggest hurdle — is scaling up manufacturing. Developing a biosensor consumable that can be produced in the millions, perform reliably for every user, and endure various shipping and environmental conditions is an enormous undertaking. Joris points out that ensuring batch-to-batch consistency for sensitive biological components is one of the toughest parts of commercializing wearable biosensor technology. Add to that the need to meet stringent regulatory standards for medical wearables, and it’s easy to see why many promising lab innovations never make it to market.
In short, the journey from a cortisol-sensing concept to a commercial wearable health device requires not only cutting-edge science but also significant investment, manufacturing expertise, and regulatory strategy.
Why Don’t We Have a Cortisol-Sensing Wearable Yet?
For Startups or Founders developing a device that incorporates novel technology or is like nothing else, the FDA breakthrough medical device program may be the best regulatory option. Learn more.
Related Resources

Nick and Nigel explore the science behind hand sanitizer formulations. They discuss how alcohol interacts with bacterial cells, why water improves its effectiveness, and what the additional ingredients in sanitizer actually do.

Scott Phillips, CEO of StarFish Medical, sits down with Peter van der Velden, Managing General Partner at Lumira Ventures, to explore the strategic thinking behind major MedTech transactions and investments.

Computer vision technologies such as convolutional neural networks and vision transformers are transforming how AI analyzes medical images, each offering distinct advantages depending on the application and computing environment.

Ariana and Mark explore how prototype strategy helps teams reduce technical risk and accelerate progress.